Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Monte Rosa Therapeutics, with seven buy ratings, one hold and one sell among nine firms. The average 12-month price target is $28.50, although several analysts recently lowered their targets to approximately $27–$28.
• The stock opened at $14.30, well below its 52-week high of $25.77. The company reported quarterly revenue of $8.97 million and an EPS loss of $0.43, both below analyst expectations, while analysts forecast a full-year loss of $1.32 per share.
• Insiders sold 81,778 shares worth about $1.77 million over the past 90 days, while institutional investors own nearly 80% of the company. BlackRock established a new position worth approximately $165.6 million during the second quarter.

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $28.50.

Several equities research analysts have issued reports on the company. Zacks Research upgraded Monte Rosa Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Guggenheim reduced their price target on Monte Rosa Therapeutics from $35.00 to $28.00 and set a "buy" rating for the company in a research report on Friday, August 7th. Wedbush lowered their target price on Monte Rosa Therapeutics from $37.00 to $27.00 and set an "outperform" rating on the stock in a research report on Monday, August 3rd. JPMorgan Chase & Co. lowered their target price on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Monte Rosa Therapeutics in a report on Monday, July 27th.

Monte Rosa Therapeutics Stock Performance

Shares of Monte Rosa Therapeutics stock opened at $14.30 on Monday. The firm has a fifty day moving average of $20.13 and a two-hundred day moving average of $18.82. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -8.12 and a beta of 1.59. Monte Rosa Therapeutics has a 52 week low of $4.51 and a 52 week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%.The company had revenue of $8.97 million for the quarter, compared to analyst estimates of $12.91 million. As a group, research analysts forecast that Monte Rosa Therapeutics will post -1.32 EPS for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In related news, Director Anthony M. Manning sold 10,000 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $23.11, for a total transaction of $231,100.00. Following the completion of the sale, the director directly owned 10,000 shares of the company's stock, valued at approximately $231,100. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Filip Janku sold 30,000 shares of the business's stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $21.42, for a total transaction of $642,600.00. Following the completion of the sale, the insider directly owned 59,992 shares of the company's stock, valued at approximately $1,285,028.64. The trade was a 33.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 81,778 shares of company stock worth $1,768,581 in the last ninety days. 6.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Monte Rosa Therapeutics during the 2nd quarter worth approximately $165,603,000. Price T Rowe Associates Inc. MD grew its position in shares of Monte Rosa Therapeutics by 10.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company's stock valued at $80,265,000 after buying an additional 481,844 shares during the last quarter. Vanguard Group Inc. increased its position in Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company's stock valued at $50,905,000 after purchasing an additional 257,547 shares during the period. State Street Corp raised its stake in Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company's stock worth $33,045,000 after buying an additional 1,260,707 shares during the last quarter. Finally, California State Teachers Retirement System lifted its stake in shares of Monte Rosa Therapeutics by 39,776.6% in the 2nd quarter. California State Teachers Retirement System now owns 1,311,543 shares of the company's stock valued at $31,739,000 after purchasing an additional 1,308,254 shares during the period. Institutional investors own 79.96% of the company's stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source